Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC StudyPR Newswire•08/09/2026•11:300 ShareWhiz InsightsGenerateNo content available.
